Investigation on a Topical Cosmetic Pain Lotion (Egyfil) for Stiffness and Pain Relief

Pain Clinical Trial

Official title:

Assessment of the "PAIN LOTION" Topical Preparation for the Relief of Stiffness, Reduced Mobility, and/or Mild to Moderate Musculoskeletal or Myofascial Pain: a Prospective Pre-market, Interventional, Single Arm Investigation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05711953
• Other study ID #: CTD-SW PAIN LOTION 2021
• Status: Completed
• Phase: N/A
• Start date: June 12, 2021
• Est. completion date: July 20, 2021

Study information

• Verified date: July 2023
• Source: Contrad Swiss SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The application of a novel topical formulation for the treatment of muscular pain and stiffness (Egyfil), containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1, is investigated to evaluate efficacy and safety in 26 patients with stiffness and pain. Single-Arm, Pre-Market, interventional study.

Description:

26 male and female patients, ranging from 24 to 78 years old, will receive Egyfil Pain Lotion given for the treatment of pain and stiffness over a three-days period. The primary objective of the study is to evaluate the clinical performance of the lotion in providing relief from stiffness, reduced mobility, and muscle tension pain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: July 20, 2021
• Est. primary completion date: July 20, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. signed participants informed consent form (ICF);

2. male or Female, aged > 18 years at the time of the signature of ICF;

3. 3 to 10 rating according to the Numerical Rating Scale (NRS), applied in participants with muscle tension pain;

4. willing to follow all study procedures;

5. willing to follow indications.

Exclusion Criteria:

1. use of analgesics within the 24 hours prior to V1;

2. damaged skin in the area of treatment;

3. infective or prior inflammatory processes near the area of treatment;

4. ongoing cutaneous allergies;

5. serious and chronical pathological skin conditions (i.e., rosacea, psoriasis, vitiligo) including diagnosticated cancer with/without ongoing antitumor therapy;

6. allergy to lotion components (aqua (water), glycerin, caprylic/capric triglyceride, aloe barbadensis leaf juice powder, simmondsia chinensis seed oil (simmondsia chinensis (jojoba) seed oil), phenoxyethanol, ammonium acryloyldimethyltaurate/vp copolymer, carbomer, tocopheryl acetate, tocopherol, benzoic acid, sodium hydroxide, sodium hyaluronate, dehydroacetic acid, ethylhexylglycerin, butyrospermum parkii butter (butyrospermum parkii (shea butter)), sorbitol, SH-polypeptide 6; SH-oligopeptide-1

7. immune system illnesses;

8. uncontrolled systemic diseases;

9. known drug and/or alcohol abuse;

10. mental incapacity that precludes adequate understanding or cooperation;

11. participation in another investigational study.

Related Conditions & MeSH terms

• Muscle Rigidity
• Pain

Intervention

Other:
• Egyfil Pain Lotion
Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1. The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product.

Locations

Country	Name	City	State
Italy	Stefano Picotti	Cardano Al Campo	Varese

Sponsors (1)

Lead Sponsor	Collaborator
Contrad Swiss SA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle Stiffness, measured by Numerical Rating Scale (NRS)	The primary efficacy endpoint of the study will be the evaluation of the clinical performance of the Egyfil, used as intended in patients affected by muscle stiffness, in terms of difference in NRS score between the end study visit and baseline visit, assessed by patients; Minimum index score: 0. Maximum index score: 10; 0 means no stiffness	3 days
Primary	Pain, measured by Numerical Rating Scale (NRS)	The primary efficacy endpoint of the study will be the evaluation of the clinical performance of the Egyfil, used as intended in patients affected by Pain, in terms of difference in NRS score between the end study visit and baseline visit, assessed by patients; Minimum index score: 0. Maximum index score: 10; 0 means no pain	3 days
Secondary	To evaluate the safety and tolerability of Pain Lotion when topically applied.	To evaluate eventual side effects of the product Egyfil through the assessment made by the Principal Investigator.; Number of Participants with adverse events.	3 days